Search

Scenarios where the results of well-intentioned scientific research can be used for both good and harmful purposes give rise to what is now widely known as the "dual-use dilemma". There has been growing debate about the dual-use nature of life science research with implications for making biological weapons. This paper reviews several controversial publications that have been the focus of debates about dual-use life science research and critically examines relevant policy developments, particularly in the United States of America. Though the dual-use dilemma is inherently ethical in nature, the majority of debates about dual-use research have primarily involved science and security experts rather than ethicists. It is important that there is more ethical input into debates about the governance of dual-use research. [ABSTRACT FROM AUTHOR]

Abstract: Biotechnological research on the deadliest pathogens has rapidly grown into a vast enterprise in the United States. With over $50 billion from federal agencies, thousands of projects are conducted at hundreds of university laboratories and other facilities in a national effort to gain the knowledge and methods for preventing the natural occurrence of pathogenic disease and protecting against bioterrorism. This paper describes this enterprise, defines several risk scenarios unrelated to terrorism which threaten lab workers and the public with lethal and contagious pathogenic disease, and evaluates the official policy framework for decision-making with regard to preventing and responding to the risk scenarios. It finds that the framework emphasizes physical security and secrecy to prevent terrorist exploitation of the enterprise, but fails to sufficiently address prevention of lab mishaps, accidental releases, and other incidents during the routine conduct of research which would expose workers and the public to the lethal pathogens. Nor does the framework effectively provide for the emergency response measures needed to prevent an accidental release of the more highly contagious pathogens from spiraling into a local or larger scale disease epidemic. These findings, supported by the growing number of near misses and small-scale incidents and lawsuits, point to major weaknesses in federal oversight and regulation, official disregard for siting criteria, inadequate self-regulation and management of lab safety practices, breakdowns in reporting systems, and obstacles to organizational learning and emergency response created by secrecy and security policies. Recommendations are made regarding these inadequacies of the federal framework and urge application of lessons learned from safety science experience with other hazardous technologies where increasing attention is being given to safety culture initiatives. [Copyright &y& Elsevier]

This paper considers the importance of collaboration for commercial biotechnology research. Biotechnology is the most research-intensive economic activity in existence today. Inter-firm collaboration is a major support of research, since most biotech firms are unable to secure all the research resources they need on their own. The ecology of biotech collaboration and its importance is considered firstly, along with the various collaborative modes and their causes. A second part then addresses the question of whether inter-firm collaboration actually strengthens research intensity. Two main types of collaborative arrangements, strategic research alliances and subcontracting, are considered. Insights into the importance of inter-firm collaborative relationships for research are provided, based on extensive empirical analyses of US commercial biotech establishments. Establishing inter-firm collaborative relationships is considered to be vital as commercial biotechnology research becomes more independent from academic research. [ABSTRACT FROM AUTHOR]

The article offers information regarding the trends in biotechnology literature in 2005. The number of output of biotech papers of the European Union outnumbered the U.S. scientists. South Korea was replaced by Belgium in the top 15 countries in terms of biotech paper output. It was also revealed that most researches deal in the field of metabolomics and nanotechnology.

The article presents data related to biotechnology research papers in the U.S. The US remains the most productive country in terms of biotech-related papers. But numbers of papers from the European Union surpassed the US last year (with Germany and the UK ahead of most EU countries); elsewhere, Korea, China and Japan also publish frequently. Some of the top cited papers, published in different journals, by field are: RNAi--Systematic functional analysis of the Caenorhabditis elegans genome using RNAi; Gene therapy--LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X2 and Nuclear transfer--Derivation of oocytes from mouse embryonic stem cells.